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ttp://dx.doi.org/10.1016/j.ajpath.2013.02.014In a successful pregnancy, the semiallogeneic fetus is not rejected by the maternal immune system,
which implies tolerance mechanisms protecting fetal tissues from maternal immune attack. Here we
report that the ICOS-B7h costimulatory pathway plays a critical role in maintaining the equilibrium at
the fetomaternal interface. Blockade of this pathway increased fetal resorption and decreased fetal
survival in an allogeneic pregnancy model (CBA female  B6 male). Locally in the placenta, levels of
regulatory markers such as IDO and TGF-b1 were reduced after anti-B7h monoclonal antibody treat-
ment, whereas levels of effector cytokines (eg, IFN-g) were signiﬁcantly increased. In secondary
lymphoid organs, enhanced IFN-g and granzyme B production (predominantly by CD8þ T cells) was
observed in the anti-B7hetreated group. The deleterious effect of B7h blockade in pregnancy was
maintained only in CD4 knockout mice, not in CD8 knockout mice, which suggests a role for CD8þ
T cells in immune regulation by the ICOS-B7h pathway. In accord, regulatory CD8þ T cells (in
particular, CD8þCD103þ cells) were signiﬁcantly decreased after anti-B7h monoclonal antibody
treatment, and adoptive transfer of this subset abrogated the deleterious effect of B7h blockade in
fetomaternal tolerance. Taken together, these data support the hypothesis that B7h blockade abro-
gates tolerance at the fetomaternal interface by enhancing CD8þ effector response and reducing local
immunomodulation mediated by CD8þ regulatory T cells. (Am J Pathol 2013, 182: 2204e2213;
http://dx.doi.org/10.1016/j.ajpath.2013.02.014)Supported by NIH grants R21-AI076794-02 and R01-AI084756-02
(I.G.) and the American Heart Association (L.V.R.).More than 50 years ago, Medawar and colleagues1 proposed
that immunological tolerance should be present during
pregnancy, to protect the fetus against an aggressive maternal
alloimmune response directed at the paternal antigens
expressed by the fetus. Since that initial hypothesis, several
mechanisms have been proposed to function actively in the
protection of the fetus from the maternal immune system.2
Among them, the presence of regulatory T cells3e7 and the
expression of immune regulatory molecules in the fetale
maternal interface have been identiﬁed as crucial factors for
fetomaternal tolerance.8e12
T cells play a major role in coordinating immune response.
Although T-cell activation depends on the initial antigen-
speciﬁc signal provided to T-cell receptors via the antigen-
loaded major histocompatibility complex, additional signalsstigative Pathology.
.provided by costimulatory molecules ﬁne-tune this response,
determining its strength, nature, and duration. Some cos-
timulatory pathways activate effector T cells, but others inhibit
T-cell activation and/or promote regulatory T cells. One of
these inhibitorymolecules is PD-L1, the expression ofwhich is
prevalent at the uteroplacental interface.11Moreover, placental
PD-L1 has been shown to protect murine allogeneic conceptus
from maternal T-cellemediated attack.11,13 Treatment of preg-
nant CBA mice with a blocking antiePD-L1 monoclonal anti-
body (mAb) resulted in loss of allogeneic but not syngeneic
conceptus. Similarly, PD-L1edeﬁcient mice had a substantial
increase in the rate of spontaneous fetal resorption andadecrease
B7h and Fetomaternal Tolerancein fetal survival.11 PD-L1 protective effect on fetomaternal
tolerance was dependent on CD4þ regulatory T cells.14
Inducible costimulatory molecule (ICOS) and its ligand
(B7h; alias B7-H2, ICOS-L) are also considered important
costimulatory molecules that inﬂuence T-cell activation and
differentiation.15 In particular, ICOSeB7h interactions have
been shown to promote regulation in a diabetes autoimmune
model and to protect against atherosclerosis in a LDL
receptor-deﬁcient mice.16,17 Whether ICOS-B7h is impor-
tant for fetomaternal tolerance remains to be determined. In
the present study, we investigated the role of the ICOS-B7h
pathway in modulating the effector/regulatory balance at the
fetomaternal interface and its role in preventing immune
attack to the fetus.
Materials and Methods
Mice
CBA/CaJ (CBA)andC57BL/6 (B6)micewere purchased from
the JacksonLaboratory (BarHarbor,ME).Mice deﬁcient in the
tryptophan-depleting enzyme Indoleamine 2,3-dioxygenase 1
(IDO-1; here, just IDO) have been described previously
[Dr. Andrew Mellor (Medical College of Georgia, Augusta,
GA)].18 Foxp3egreen ﬂuorescent protein (GFP) reporter
mice [a kind gift from Dr. Yurij Rudensky (University of
Washington)] have been described previously.19 Animal care
and experimental procedures followed institutional guidelines.
Timed Matings and Resorption Rates
Virgin CBA/CaJ females (8 to 10 weeks of age) were mated
with C57BL/6 (allogeneic) or CBA/CaJ (syngeneic) males (6
to 12 weeks of age). Females were inspected daily for vaginal
plugs and the day a plug was observed was designated as day
0.5 of pregnancy. Plugged females were either monitored
until parturition, when the number of pups born was recor-
ded, or they were sacriﬁced at 10.5, 13.5, and 16.5 days after
copulation (days post coitum, dpc) for examination of the
number of implanting embryos and resorbing sites. The rate
of resorption was calculated by counting the number of
resorbing versus healthy embryos at 13.5 dpc.
Treatment Protocol
Pregnant females were injected intraperitoneally at 6.5, 8.5,
10.5, and 12.5 dpc with anti-mouse B7h mAb (clone
HK5.3) or polyclonal rat IgG (control) at a dosage of 500 mg
(at 6.5 and 8.5 dpc) and 250 mg (at 10.5 and 12.5 dpc). For
certain experiments, antieCTLA-4 mAb (AC10-4F10) was
used with a similar dosing protocol.
Histology
At predetermined intervals, spleen and placentae were
removed for histological analysis and immunostaining.The American Journal of Pathology - ajp.amjpathol.orgPlacentae were embedded in Tissue-TekOCT optimal cutting
temperature compound (Sakura Finetek, Torrance, CA) and
were snap-frozen in liquid nitrogen. Immunohistochemistry
was performed on frozen tissue sections (5 mm thick) with
antibodies to B7h (clone HK5.3, rat IgG2a). Sections were
ﬁxed in cold acetone, washed in PBS, quenched in 0.3%
hydrogen peroxide in PBS, washed again in PBS, blocked
with normal serum, and incubated with primary antibody
overnight at 4C. After another PBS wash, slides were incu-
bated with biotinylated antibody for 40 minutes at room
temperature, followed by another incubation with avidin-
conjugated peroxidase (Vectastain ABC vector Elite kit;
Vector Laboratories, Burlingame, CA) before being devel-
oped with 3,30-diaminobenzidine. The tissue sections were
ﬁnally counterstained with hematoxylin; positive staining
was indicated by a red-brown coloration, as described
previously.11 Isotype-matched antibodies (rat IgG2a or rat
IgG2b) were used as negative controls. Immunostaining was
also performed with cytokeratin 7 antibody (polyclonal,
rabbit IgG), to assess the colocalization of B7h to trophoblast
cells.
ELISPOT Assay
Splenocytes from CBA/CaJ (C57BL/6) pregnant mice
treated with anti-B7h mAb or control IgG were obtained as
single-cell suspensions and used as responder cells. Irradi-
ated (30 Gy) splenocytes from C57BL/6 and CBA/CaJ
males were used as stimulators. The enzyme-linked immu-
nosorbent spot (ELISPOT) assay was adapted to measure
cells secreting IFN-g and IL-4, as described previously.11
Flow Cytometric Analysis
Placentae and spleen were removed from pregnant mice at
deﬁned numbers of days after copulation. Spleens were
processed and single-cell suspensions were prepared.
Placentae were washed brieﬂy in cold PBS and diced before
digestion in medium containing collagenase IV (Roche
Applied Science, Indianapolis, IN) and DNase I (Sigma-
Aldrich, St. Louis, MO) for 1 hour. After single-cell
suspensions were prepared, leukocytes were separated
using Percoll equilibrium density gradients between the
high and low densities (1.095 and 1.030, respectively). The
isolated cells were then washed twice and counted. To study
the phenotype of splenocytes and cells inﬁltrating the
placenta, staining was performed with antieCD4-PerCP,
antieCD8-APC, antieCD25-ﬂuorescein isothiocyanate,
antieFoxp3-phycoerythrin (PE), antieCD103-ﬂuorescein
isothiocyanate, antieCD44-APC, and antieCD62L-PE
mAbs in the case of spleens/lymph nodes, and with
antieCD45-APC (pan-leukocyte marker), antieIFN-g-PE,
and antieFoxp3-PE mAbs for cells inﬁltrating the placenta.
Intracellular IFN-g and Foxp3 staining were performed
using a Cytoﬁx/Cytoperm intracellular staining kit (BD
Biosciences, San Jose, CA). Brieﬂy, cells were blocked2205
Riella et alwith Fc block (to prevent nonspeciﬁc binding), ﬁxed, and
permeabilized for 16 hours in the dark at 4C and then were
stained for IFN-g for 60 minutes. All antibodies and
reagents for ﬂow cytometry analysis were purchased from
BD Biosciences or eBioscience (San Jose, CA). Cells were
analyzed on a FACSCalibur ﬂuorescence-activated cell-
sorting system using CellQuest software version 5.2 (both
from BD Biosciences).
Microbead Cytokine Assay
At 8 weeks of age, CBA/CaJ females were mated with
C57BL/6 males and were injected with four doses of anti-
B7h monoclonal antibody according to the protocol
described above. Lymphocytes were isolated from spleen
and lymph nodes of pregnant females at 11.5 and 13.5 dpc
and were cultured in RPMI 1640 medium with 10% fetal
bovine serum in 96 well plates at a density of 0.5 106 cells/
well. The stimulator cells were isolated from C57BL/6 males,
irradiated with 30 Gy, and added to the culture at a density of
0.5  106 cells/well. The mixed lymphocyte culture was
incubated for 72 hours at 37C in 5% CO2. Using a Luminex
(Austin, TX) microbead assay, we measured the level of
TGF-b1 and IL-17 in cell culture supernatant at 48 and
72 hours according to the manufacturer’s instructions. A
Luminex 100 IS instrument with STarStation acquisition
software version 2 (Applied Cytometry Systems, Shefﬁeld,
UK) was used to process the data. All samples were run in
single wells, except that the standard curve points were run in
duplicate according to the manufacturer’s recommendations.
Isolation of Effector CD8þ T Cell Population
Female C57/BL6 Foxp3.GFP reporter mice (in which the
sequence encoding GFP is knocked in into the gene
encoding Foxp3) were mated with CBA/CAJ males and
were inspected daily for plugs. Females with visible plugs
were considered at day 0.5 of pregnancy and received four
intraperitoneal injections of anti-B7h (or control IgG) mAb
according to the protocol described above. At 11.5 and
13.5 dpc, spleen and lymph nodes (uterine, renal, pancre-
atic, inguinal) were harvested and were mechanically dis-
rupted to prepare single-cell suspensions. Cells from treated
and control mice were pooled, and CD8þ T cells were
puriﬁed using a CD8þ T-cell isolation kit (Miltenyi Biotec,
Bergisch-Gladbach, Germany; Auburn, CA) according to
the manufacturer’s instructions. Isolated CD8þ T cells were
then fractioned into Foxp3.GFPþ cells and GFP cells with
a MoFlo cell sorter (Beckman Coulter, Brea, CA).
In Vitro Suppression Assay and Adoptive Transfer of
CD8þ Regulatory T Cells
To assess the regulatory function of CD8þCD103þ T cells
in vitro, a mixed lymphocyte reaction assay was set up in
which T cells isolated from spleen/lymph nodes of pregnant2206CBA/CaJ females were cultured with irradiated B6 spleno-
cytes and CD8þCD103þ T cells at various ratios (1:0, 1:4,
1:8) for 72 hours. Cells were pulsed with [3H] thymidine
(1 mCi per well) for the ﬁnal 16 hours of incubation, and
incorporation of [3H] thymidine was measured with
a MicroBeta liquid scintillation counter (PerkinElmer, Wal-
tham,MA). The regulatory function of CD8þCD103þ T cells
was assessed by the suppressive effect on the proliferation of
effector T cells. Whole T cells were isolated by negative
selection with a mouse Pan T-cell isolation kit II (catalog no.
130-095-130; Miltenyi Biotec), and CD8þCD103þ cells
were ﬂow-sorted after staining with ﬂuorochrome antibodies
for CD8 and CD103, achieving greater than 99% purity.
Using a similar isolation technique as described above,
CD8þCD103þ cells were adoptively transferred to pregnant
CBA/CaJ females (350,000 cells) intraperitoneally 3 days
after plugging, and fetal resorption was assessed at 13.5 dpc
in the IgG-treated and the anti-B7h-treated groups.
RNA Extraction and qPCR
CD8þGFPþ and CD8þGFP cells were then suspended in
TRIzol reagent (Life TechnologieseInvitrogen, Carlsbad,
CA), and total RNA isolation was performed according to the
manufacturer’s protocol. RNA was treated with DNase (Life
TechnologieseInvitrogen), and 5mg ofRNAwas then reverse-
transcribed to synthesize 60 mL of cDNA. Each quantitative
real-time PCR (qPCR) reaction consisted of 20 mL containing
250 ng of cDNA, 10 mL of SYBR Green master mix
(Life TechnologieseApplied Biosystems, Foster City, CA),
and 250 nmol of sense and antisense primer. Primers were
designed using Primer Express software version 2.0 (Life
TechnologieseInvitrogen). The reaction conditionswere 50C
for 2 minutes, 95C for 10 minutes, followed by 40 cycles of
95C for 15 seconds and 60C for 1 minute; ﬂuorescence was
measured during the annealing/extension phase. The following
primer sequences were used: B7h forward 50-TCTTGGAA-
GAGGTGGTCAGG-30, reverse 50-TGGAGCTATCAGAGGT-
GCTG-30; IDO forward 50-CCTTCTGGGAATAAAACAC-
GA-30, reverse 50-GGCTGGAGGCATGTACTCTC-30; IL-
10 forward 50-ATCGATTTCTCCCCTGTGAA-30, reverse
50-TGGCCTTGTAGACACCTTGG-30; PD-L1 forward 50-
AAGCGAATCACGCTGAAAGT-30, reverse 50-ATGCTCA-
GAAGTGGCTGGAT-30; IL-17 forward 50-TTCAGGGTCG-
AGAAGATGCT-30, reverse 50-AAACGTGGGGGTTTCT-
TAGG-30; IL-4 forward 50-TCATCGGCATTTTGAACG-
AG-30, reverse 50-CGTTTGGCACATCCATCTCC-30; IL-5
forward 50-AAAGAGAAGTGTGGCGAGGAGA-30, reverse
50-CACCAAGGAACTCTTGCAGGTAA-30; IFN-g forward
50-AACGCTACACACTGCATCTTGG-30, reverse 50-GC-
CGTGGCAGTAACAGCC-30; granzyme B forward 50-CC-
CAGGCGCAATGTCAAT-30, reverse 50-CCAGGATAA-
GAAACTCGA-30; GAPDH forward 50-GGCAAATTCAA-
CGGCACAGT-30, reverse 50-AGATGGTGATGGGCTTC-
CC-30; and TGF-b1 forward 50-TGAGTGGCTGTCTTT-
TGACG-30, reverse 50-GGTTCAGTCATGGATGGTG-30.ajp.amjpathol.org - The American Journal of Pathology
B7h and Fetomaternal ToleranceExpressionwasmeasured as copies of any given gene divided
by copies of the housekeeping gene GAPDH.
Statistical Analysis
The nonparametric U-test was used for comparison of
means. P < 0.05 was considered statistically signiﬁcant.
Results
Expression of B7h and ICOS at the Fetomaternal
Interface
First, we studied expression of B7h (ICOS-L) in the placenta.
Placentae were removed at 8.5, 12.5, and 16.5 dpc from
pregnant CBA/CaJ females mated with C57BL/6 (B6) males.
Expression of B7h was determined by qPCR (Figure 1A).
Immunohistochemical staining on cryosection of placenta at
12.5 dpc localized expression of B7h in the maternal decidua
of placenta (Figure 1B) and not the decidua basalis; these two
areas are structurally distinct under the microscope. This
expression pattern differs from that observed for PD-L1, in
which expressionwas localized in the decidua basalis.11B7h is
not expressed on trophoblast cells, as evident from costaining
with cytokeratin 7 antibody (data not shown). Furthermore,
B7h was not expressed in placental sections obtained from
syngeneicmatings (CBACBA) (Supplemental Figure S1A).
Speciﬁcity of this expression is demonstrated by lack of
expression of B7h in a B7h-deﬁcient on B6 background mice
(Supplemental Figure S1B).
To evaluate the binding partner of B7h, the percentage of
ICOS expression was characterized by ﬂow cytometry in
leukocytes isolated from placenta. A high expression of
ICOS was observed in CD8þCD103þ T cells (65.9% 1.9)
and CD4þFoxp3 cells (50.2  1.2%), compared with
CD4þFoxp3þ (20.4  2.3%), CD8þFoxp3þ (23.7  6.5%),
CD8þFoxp3 (21  2.4%), and CD8þCD103 cells (1.2 
0.3%) (Figure 1C).Figure 1 B7h/ICOS expression at the fetomaternal interface of CBA/CaJ mice.
were removed at 8.5, 12.5, and 16.5 dpc, and B7h expression was analyzed by q
Representative photomicrographs show staining in the whole decidua (md, mate
Original magniﬁcation (4 or 20) is indicated for each image. Results are rep
leukocytes isolated from placenta at 12.5 dpc. Data are expressed as means  S
The American Journal of Pathology - ajp.amjpathol.orgEffect of B7h Blockade on the Rate of Spontaneous
Resorption and Litter Size
To study the role of B7h in fetomaternal tolerance, we used
a model of allogeneic pregnancy, mating CBA/CaJ females
with C57BL/6 males. The reported rate of spontaneous
resorption in this model is approximately 20%.10,20 We
assessed the rate of resorption and litter size after blocking
B7h with a monoclonal antibody. The resorption rate
increased signiﬁcantly, from 26% in the control IgG group
to 46% in the anti-B7h mAbetreated group (P Z 0.0014)
(Figure 2A). We conﬁrmed our results by assessing the
number of pups born from this same allogeneic mating.
B7h-treated mice had a mean litter size of 5.5 pups,
compared with 7.2 in the control IgG group (P Z 0.0419)
(Figure 2B). The effect of anti-B7h antibody treatment was
alloantigen speciﬁc, because there was no increase in
resorption in CBA/CaJCBA/CaJ syngeneic mating after
treatment with this antibody (data not shown).B7h Blockade Enhances Effector Function But
Decreases Regulation in the Placental Interface
The placenta is the central organ involved in immune regu-
lation during pregnancy, because it contains both maternal
and fetal cells in close proximity.2 To characterize the role of
B7h in fetomaternal tolerance, we evaluated effector and
regulatory markers in the placenta. First, we isolated leuko-
cytes (CD45þ) from the placenta and observed a signiﬁcant
increase in the percentage of IFN-geproducing leukocytes
after allostimulation in the anti-B7hetreated mice, compared
with controls (11  1.28 versus 7  0.36; P Z 0.03)
(Figure 3A). Next, we quantiﬁed regulatory markers in the
placenta by qPCR. B7h blockade signiﬁcantly decreased
mRNA of the regulatory molecules TGF-b1, IDO, and
CTLA-4 (Figure 3, BeD). IL-10 showed a trend toward lower
expression, but this did not reach statistical signiﬁcanceVirgin female CBA/CaJ mice were mated with C57BL/6 males. A: Placentae
PCR. B: Placentae at 12.5 dpc were also immunostained for B7h (arrows).
rnal decidua); trophoblastic giant cells (tgc) of placenta are also shown.
resentative of two independent sets of experiments. C: ICOS expression in
EM. n Z 3 per experiment.
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Figure 2 B7h blockade signiﬁcantly increases fetal resorption and
reduces litter size in the CBA/CaJC57BL/6 allogeneic pregnancy model.
A: Pregnant CBA/CaJ (C57BL/6) females were injected intraperitoneally
with anti-B7h mAb or control IgG, and the fetal resorption rate was deter-
mined at 13.5 dpc in pregnant CBA/CaJ mice of both groups. There was
a signiﬁcant increase in fetal resorption rate in the anti-B7hetreated mice,
compared with control. B: Somemice treated with anti-B7h or rat control IgG
were allowed to go to term and litter size was recorded. There was a signif-
icant reduction in litter size in the anti-B7hetreated mice, compared with
control. n Z 21 (A) or 11 (B), controls; n Z 30 (A) or 12 (B), treatment
group. Horizontal bars indicate means.
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Figure 3 Characterization of placental markers after anti-B7h treat-
ment. A: Percentage of IFN-geproducing leukocytes (CD45þ) isolated from
placenta of anti-B7hetreated versus control IgG-treated mice at 13.5 dpc.
BeD: qPCR analysis of TGF-b1, IDO, and CTLA-4 in the placenta from both
groups at similar time points . Data are expressed as means  SEM. nZ 8
or 9 per group.
Riella et al(1.45  0.45 versus 2.27  0.45, respectively; P Z 0.27).
Because the coinhibitory molecule PD-L1 is crucial for fetal
tolerance,11 PD-L1 expression was also measured, but was
found to be similar in both groups (data not shown). In sum,
B7h blockade signiﬁcantly affected immunoregulation at the
fetomaternal interface.
Both CTLA-4 and IDO Regulatory Components Play
a Role in the Deleterious Effect of B7h Blockade
Because expression of both IDO and CTLA-4 was down-
regulated in the placentae of the anti-B7h mAbetreated
group, we decided to further examine whether these regula-
tory components are functionally important for the enhanced
fetal loss observed on B7h blockade. Allogeneically mated
pregnant IDO-deﬁcient females treated with anti-B7h mAb
did not exhibit a signiﬁcant change in the rate of fetal
resorption, compared with IgG-treated controls (n Z 7;
P Z 0.25) (Supplemental Figure S2A). Furthermore, using
a blocking antibody against CTLA-4 (antieCTLA-4 mAb) in
wild-type allogeneic pregnancy model (CBAB6), we
observed that neutralization of CTLA-4 also abrogated the
enhanced fetal loss observed with anti-B7h treatment (nZ 4
to 7; P Z 0.42) (Supplemental Figure S2B). These data
indicate that the increased rate of fetal resorption after B7h2208blockade is in part mediated by regulatory signals (eg, IDO
and CTLA-4).
Effect of anti-B7h mAb in Secondary Lymphoid Organs
To assess the effect of B7h blockade on the periphery, we
started by comparing the frequency of CD4þ and CD8þ
effector memory T cells in the spleen and lymph nodes of
treated and control pregnant CBA/CaJ (C57BL/6) females
at 11.5 and 13.5 dpc. We observed a transient decrease in the
percentage of CD4þ effector memory T cells in the anti-
B7hetreated group at 11.5 dpc (P Z 0.0003) (Figure 4A),
whereas the percentage of CD8þ effector memory T cells was
the same between groups (P Z 0.41) (Figure 4B). At 13.5
dpc, CD4þ and CD8þ T-cell subsets were similar in number
in both groups (data not shown). Next, we performed mixed
leukocyte cultures in vitro to further characterize the
alloimmune response. For these studies, splenocytes from
pregnant allogeneically mated CBA females treated with
anti-B7h mAb or control IgG were isolated at 11.5 dpc and
were cultured in the presence of irradiated splenocytes from
C57BL/6 males. An ELISPOT assay was performed for
determining the frequency of IFN-geproducing cells.
For monitoring other cytokines, cell culture supernatants
were collected and analyzed using a Luminex microbead
assay. We observed an increase in IFN-g production by
splenocytes from the anti-B7hetreated group (17  4 spots
versus 5  1 spots for controls; nZ 5; PZ 0.03), although
the levels were low overall. IL-4 and IL-17 production didajp.amjpathol.org - The American Journal of Pathology
Figure 4 Analysis of effector memory T cells
on spleens after anti-B7h treatment. A and B:
Splenocytes from CBA/CaJ (C57BL/6) pregnant
mice treated with anti-B7h mAb or control IgG
were processed at 11.5 dpc and stained for CD4 (A)
and CD8 (B) in combination with effector memory
markers (CD44, CD62L). Effector memory T cells
were deﬁned by high expression of CD44 and low
expression of CD62L. Quantiﬁcation data are
expressed as means  SEM. nZ 7 or 8 per group.
B7h and Fetomaternal Tolerancenot differ signiﬁcantly between groups (data not shown). In
addition, there was a trend toward lower TGF-b1 levels in
the anti-B7hetreated group, compared with controls, after
48 to 72 hours of incubation. Using intracellular cytokine
staining after allostimulation, we determined that the major
producers of IFN-g in the periphery were CD8þ T cells and
that the percentage of CD8þ IFNgþ T cells was signiﬁ-
cantly higher in the spleen and lymph nodes of anti-
B7hetreated mice, compared with controls (15.4  4 versus
0.01  0.006 for controls; n Z 5; P Z 0.01). These data
suggest that B7h blockade leads to enhanced alloimmunity
in pregnancy, with a predominant increase in IFN-ge
producing CD8þ cells.
CD8þ T Cells Play a Crucial Role in Fetomaternal
Tolerance on B7h Blockade
To further investigate the roles of CD4þ and CD8þ T cells
in B7h-mediated fetomaternal tolerance, we used CD4þ and
CD8þ T-celledeﬁcient mice. Injection of anti-B7h mAb
into CD4þ T-celledeﬁcient mice resulted in a statistically
signiﬁcant decrease in litter size (P Z 0.001) (Figure 5A),
whereas injection of anti-B7h mAb into mice deﬁcient for
CD8þ T cells abrogated this deleterious effect on litter size
(P Z 0.47) (Figure 5B). These ﬁndings in CD8þ T-celle
deﬁcient mice suggest a critical role for CD8þ cells in
mediating the effects of B7h blockade on tolerance at the
fetomaternal interface.
Regulatory CD8þ T Cells Are Signiﬁcantly Affected by
B7h Blockade
To evaluate the role of regulatory T cells in our model, we
started by measuring the frequency of CD4þ regulatoryThe American Journal of Pathology - ajp.amjpathol.orgT cells in spleens and lymph nodes by ﬂow cytometry. No
differences in the percentage of CD4þCD25þFoxp3þ cells
was observed between pregnant CBA/CaJ female mice
treated with anti-B7h mAb or control IgG (Supplemental
Figure S3). There was, however, a signiﬁcant decrease in
two subpopulations of CD8þ regulatory T cells character-
ized by expression of Foxp3 or CD103 (P < 0.001)
(Figure 6A).
To further characterize these regulatory T-cell subsets, we
used a Foxp3-GFP reporter mouse; this model permits the
isolation of CD8þGFP.Foxp3þ and CD8þGFP.Foxp3
cells from the spleen and lymph nodes of pregnant females.
The yield of CD8þFoxp3þ cells after ﬂow sorting was very
low, even after pooling samples from more than one mouse.
We therefore used qPCR to compare the cytokine proﬁle
between groups. IFN-g expression on CD8þFoxp3þ cells
was similar between the anti-B7hetreated and IgG control
groups, whereas expression of IL-4, IL-5, IL-10, and IL-17
was undetectable (data not shown). Analysis of the
CD8þFoxp3 subset by qPCR showed a 5.3-fold increase
in granzyme B expression and a 2.6-fold increase in IFN-g
expression in CD8þFoxp3 cells isolated from anti-B7he
treated group, compared with controls. These ﬁndings are in
agreement with our observations (noted above) in the
placenta and in whole splenocytes. In addition, we deter-
mined IFN-g production by the other subset of regulatory
CD8þ cells (ie, CD8þCD103þ cells). These cells demon-
strated a lower production of IFN-g by intracellular cyto-
kine staining after allostimulation in vitro, compared with
CD8þCD103 cells (Figure 6B). Furthermore, ﬂow-sorted
CD8þCD103þ T cells were able to suppress T-cell prolif-
eration in vitro (Figure 6C), supporting the evidence of
a regulatory role for this subset.21 Last of all, adoptive
transfer of CD8þCD103þ cells to pregnant CBA/CaJ2209
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Figure 5 Reduced litter size in CD4þ T-celledeﬁcient but not CD8þ
T-celledeﬁcient mice after anti-B7h treatment. CD4þ (A) or CD8þ (B)
T-celledeﬁcient females on C57BL/6 background were mated with CBA/CaJ
males and treated with anti-B7h mAb or control IgG. Litter size was deter-
mined at term. There was a signiﬁcant reduction in litter size in CD4-deﬁcient
mice but not in CD8-deﬁcient mice. nZ 8 or 9 per group. KO, knockout.
Riella et alfemales abrogated the increased fetal resorption elicited by
B7h blockade (Figure 6D). Taken together, these ﬁndings
suggest that ICOSeB7h interaction is important for the
generation of regulatory CD8þ cells and that blockade of
B7h signiﬁcantly affects immune regulation at the placental
interface.
Discussion
The ICOSeB7h interaction is a complex costimulatory
pathway that actively participates in the process of T-cell
activation, differentiation, and function.22,23 In addition to
its role in effector T cells, this pathway also seems to be
important for immune regulation. ICOS-B7h signaling was
shown to be critical for the generation of regulatory T cells,
capable of suppressing pulmonary inﬂammation in amodel of
airway hyperactivity.24 ICOSeB7h interaction was also
shown to be essential for oral mucosal tolerance in a model in
which the encephalitogenic myelin oligodendrocyte glyco-
protein peptide MOG35e55 is administered orally for protec-
tion against experimental autoimmune encephalomyelitis.252210Furthermore, ICOS blockade exacerbated diabetes in
BDC2.5 transgenic NODmice, and this effect was dependent
on regulatory T cells.16 Interestingly, ICOSeB7h interaction
has been shown to have diverse effects, depending on the
disease model studied, the type of immune response elicited,
and the timing of ICOS-B7h blockade.15 For example, ICOS
blockade prolonged cardiac allograft survival in a fully HLA-
mismatched murine transplant model, in particular when the
protocol involved delayed blockade.23 In contrast, early
ICOS blockade accelerated rejection in a minor mismatched
cardiac transplant model.23 Some of these discrepancies seem
to be related to the diverse role of ICOS in both effector and
regulatory T cells.26 Consistent with report of suppressive
effects of the ICOS-B7h pathway, blockade of B7h in our
allogeneic pregnancy model enhanced fetal resorption and
decreased the litter size (Figure 2), with associated reduction
in bothCD4þ effectormemory T cells andCD8þ regulatory T
cells.
In general, ICOS signaling appears to support the
expansion and survival of differentiated T cells, and,
depending on the dominant phenotype of the immune
response, it might either accelerate the disease process or
provide protection against it.26e28 It does seem that in
noneTh1 dominant models, absence of this pathway is
deleterious. An example would be asthma, which is caused
by a Th2-driven immune response and blockade of ICOS-
B7h exacerbates disease.24 In healthy pregnancy, the
balance of Th1/Th2 cytokines is considered to be of critical
importance, with dominance of a Th2-type immunity and
suppression of Th1,29e32 ﬁtting as a noneTh1 dominant
model. Indeed, augmented Th1 response is associated with
increased rates of abortion.33,34 In supporting of the above
hypothesis, we observed an expansion of IFN-geproducing
leukocytes both in the placenta and peripherally in anti-
B7hetreated pregnant mice, suggesting that an enhanced
Th1 response is a contributing factor in the increased fetal
resorption rate observed as a result of B7h blockade. In
another study, however, in vitro cocultures of JEG-3 cells
(an extravillous trophoblast cell line with documented B7h
expression) with T cells and anti-CD3 mAb led to increased
IFN-g secretion.35 We believe that the differences between
our present in vivo ﬁndings and these other in vitro obser-
vations are related to the experimental setting and reﬂect
some of the challenges in attempts to examine isolated cell
interactions in vitro with exogenous stimuli (anti-CD3) that
do not truly reﬂect the placental microenvironment.
ICOS signaling has been reported to also play a critical
role in Th17 differentiation, inducing expression of the
transcription factor c-MAF and consequent IL-21 produc-
tion.36,37 In the present study, however, we could not detect
any differences in IL-17 production after B7h blockade,
neither in the periphery nor locally at the fetomaternal
interface. Moreover, IL-17 has been detected only in very
low levels at the fetomaternal interface in general.34,38
Whether Th17 cells can play a deleterious role in fetoma-
ternal tolerance still remains to be determined.ajp.amjpathol.org - The American Journal of Pathology
Figure 6 Evaluation of CD8þ regulatory T cells
on B7h blockade. Splenocytes from CBA/CaJ
(C57BL/6) pregnant mice treated with anti-B7h
mAb or control IgG were processed at 11.5 dpc.
A: Representative dot plots of CD8þFoxp3þ and
CD8þCD103þ subpopulations are shown (left
panel), with the percentages of these subsets
combining multiple experiments (right panel).
B: Determination of IFN-g production by intracel-
lular cytokine staining in CD8þCD103 and
CD8þCD103þ cells. C: In vitro suppression assay of
CD8þ regulatory T cells (ﬂow-sorted CD8þCD103þ
cells) in combination with effector T cells at
different ratios, as described under Materials and
Methods. D: Adoptive transfer of CD8þ regulatory
T cells (ﬂow-sorted CD8þCD103þ cells) into preg-
nant CBA/CaJ females at 3 days after plugging.
Fetal resorption was assessed at 13.5 dpc in IgG and
anti-B7hetreated groups. nZ 4 per group.
B7h and Fetomaternal ToleranceRegulatory T cells are critical for the maintenance of
tolerance at the fetomaternal interface3,39 and signiﬁcant
reductions in regulatory T cells (CD4þCD25þ) at the decidual
level and in peripheral blood specimens have been demon-
strated in spontaneous abortions, compared with healthy
pregnancies.5 Most of the studies in pregnancy have shown
a role for CD4þ regulatory T cells. However, Shao et al40
reported that placental trophoblasts are able to generate
a subpopulation of regulatory CD8þ cells that express
CD103. In another study, CD103 was identiﬁed as a marker
of alloantigen-induced regulatory CD8þ T cells, and
CD8þCD103þ T cells were shown to have immunosuppres-
sive function with low proliferative and cytotoxic capacity.21
Consistent with these ﬁndings, in the present study we
observed a predominant reduction in regulatory CD8þ T cellsThe American Journal of Pathology - ajp.amjpathol.orgas a result of B7h blockade. Two different subsets of regula-
tory CD8þ T cells were identiﬁed by the coexpression of
either Foxp3 or CD103 (Figure 6A). The effect on the latter
was observed to be numerically more signiﬁcant. Further-
more, CD8-deﬁcient mice treated with anti-B7h mAb did not
experience the same enhanced fetal resorption, indicating that
the deleterious effect of ICOS-B7h blockade is dependent on
CD8þ cells. The adoptive transfer of CD8þ regulatory T cells
abrogated the increased fetal resorption in anti-B7hetreated
group, conﬁrming the key role of this subset in fetomaternal
tolerance (Figure 6D).
In accord with other reports,35,41 ICOS expression was
predominant on placental T cells and B7h was present in
placental decidua. Our study expanded those ﬁndings by
showing the greatest expression of ICOSby theCD8þCD103þ2211
Riella et alT-cell subset and B7h in the maternal decidua. In humans, B7h
expression is present in the placenta throughout gestation.41
Although ICOS has been shown to be important for
CD4þFoxp3þ regulatory T-cell homeostasis, with ICOS-
deﬁcient mice exhibiting a reduced number of CD4þFoxp3þ
regulatory T cells,26 the exact of role of ICOSeB7h interaction
in the generation of regulatory CD8þ cells still remains to be
determined. Based on the high expression of ICOS on
CD8þCD103þ cells and the lower numbers of this subset on
B7h blockade, ICOS-B7h signaling might be important for the
generationof thisCD8þ regulatoryT-cell subset. Priorwork on
CD4þ regulatory T cells showed that two subsets of regulatory
CD4þ cells were differently regulated by signaling through
ICOS orCD28; whether this is also true for CD8þ regulatory T
cells warrants further investigation.42
Regulatory T cells exert their suppressive effect through
multiple mechanisms, including secretion of inhibitory
cytokines (eg, TGF-b1, IL-10) and cytotoxic enzymes (eg,
granzyme B), as well as direct cellecell interaction via
inhibitory receptors (eg, CTLA-4). We have previously
shown that the PD-1ePD-L1 pathway plays a critical role in
tolerance at the fetomaternal interface and that this effect is
dependent on regulatory T cells.11,13,14 In the present study,
however, we did not observe a signiﬁcant difference of PD-
L1 expression in the placenta of anti-B7hetreated mice,
suggesting that the deleterious effect of B7h blockade is
independent of PD-L1 signaling.
IDO has also been shown to play an important role in
conferring tolerance at the fetomaternal interface,10 and inhi-
bition of IDO was shown to result in increased fetal rejection
associated with massive T-cell inﬁltration and complement
deposition at the uteroplacental interface.20 In the present study,
blockadeof the ICOS-B7hpathway resulted indown-regulation
of IDO, TGF-b1, and CTLA-4 locally at the fetomaternal
interface. TGF-b1 is an important regulator of tolerance during
pregnancy and acts via multiple mechanisms.43e45 Interaction
of CTLA-4 with the costimulatory molecule B7 (CD80/86)
expressed on the dendritic cells induces the activity of IDO.46
CTLA-4 expressed on regulatory T cells has been shown to
regulate IDO expression on decidual and peripheral blood
antigen-presenting cells, and in spontaneous abortion the
expression of CTLA-4 on regulatory T cells was reduced.47
Further investigation will be required to determine the exact
relationship between ICOSeB7h interaction and IDO, and how
B7hblockade affects thegenerationofCD8þ regulatoryT cells.
Our studies with IDO-deﬁcient mice and with antieCTLA-4
mAb in combination with anti-B7h mAb suggest that they are
deﬁnitely interconnected.
In summary, the present ﬁndings demonstrate that the
ICOS-B7h pathway plays a critical role in the regulation of
fetomaternal tolerance by enhancing IFN-g CD8þ effector
response and by reducing local immunomodulation medi-
ated by CD8þ regulatory T cells. Further studies should
attempt to elucidate the exact function of ICOS-B7h in
CD8þ regulatory T-cell generation and the potential inter-
actions with CTLA-4 and IDO pathways in pregnancy.2212Supplemental Data
Supplemental material for this article can be found at
http://dx.doi.org/10.1016/j.ajpath.2013.02.014.References
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